Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3A Clinical benefit achieved from 1st line endocrine therapy in all patients

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Endocrine therapy 1 st line
N 223
N of CB (%) 159 (71.3%)
Median DOR with CB (months) 22+(7–117)
N still receiving treatment 50
  1. + = including patients who are still on treatment, therefore would have additional duration of response on a later analysis; CB = Clinical Benefit; DOR = Duration of Response